Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients

Abraham, 2000, Renal salt and water handling in congestive heart failure, 253

Lee, 1986, Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure, Circulation, 73, 257, 10.1161/01.CIR.73.2.257

Lee, 2003, Predicting mortality among patients hospitalized for heart failure, JAMA, 290, 2581, 10.1001/jama.290.19.2581

Anderson, 1974, Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion, J Clin Invest, 54, 1473, 10.1172/JCI107895

Kim, 1990, Arginine vasopressin gene expression in chronic cardiac failure in rats, Kidney Int, 38, 818, 10.1038/ki.1990.276

Xu, 1997, Upregulation of aquaporin-2 water channel expression in chronic heart failure rat, J Clin Invest, 99, 1500, 10.1172/JCI119312

Szatalowicz, 1981, Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure, N Engl J Med, 305, 263, 10.1056/NEJM198107303050506

Rigger, 1982, Antidiuretic hormone in congestive heart failure, Am J Med, 72, 49, 10.1016/0002-9343(82)90576-9

Rondeau, 1982, High plasma antiduretic hormone in patients with cardiac failure, Miner Electrolyte Metab, 8, 267

Goldsmith, 1986, Arginine vasopressin and the renal response to water loading in congestive heart failure, Am J Cardiol, 58, 295, 10.1016/0002-9149(86)90065-2

Yamamura, 1992, Characterization of a novel aquaretic agent, OPC-31260, as an effective, nonpeptide vasopressin V2 receptor antagonist, Br J Pharmacol, 105, 787, 10.1111/j.1476-5381.1992.tb09058.x

Serradeil-Le Gal, 2002, Nonpeptide vasopressin receptor antagonists, Prog Brain Res, 139, 197

Burrell, 1998, Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat, Am J Physiol, 275, H176

Naitoh, 1994, Effect of oral AVP antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs, Am J Physiol, 267, H2245

Chan, 1998, VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist, Adv Exp Med Biol, 449, 439, 10.1007/978-1-4615-4871-3_55

Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580

Martin, 1999, Selective V2-receptor vasopressin antagonist decreases urinary aquaporine-2 excretion in patients with chronic heart failure, J Am Soc Nephrol, 10, 2165, 10.1681/ASN.V10102165

Gerbes, 2003, Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist, Gastroenterology, 124, 933, 10.1053/gast.2003.50143

Wong, 2003, A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia, Hepatology, 37, 182, 10.1053/jhep.2003.50021

Gheorghiade, 2004, Effect of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure, JAMA, 291, 1963, 10.1001/jama.291.16.1963

Gheorghiade, 2003, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure, Circulation, 107, 2690, 10.1161/01.CIR.0000070422.41439.04

Palm, 1999, V2-vasopressin receptor antagonist—mechanism of effect and clinical implication in hyponatremia, Nephrol Dial Transplant, 14, 2559, 10.1093/ndt/14.11.2559

Tomaselli, 1994, Sudden cardiac death in heart failure, Circulation, 90, 2543, 10.1161/01.CIR.90.5.2534

Okada, 1993, Enhancement of vascular action of argenine vasopressin by diminished extracellular sodium concentration, Kidney Int, 44, 755, 10.1038/ki.1993.310